Displaying drugs 11601 - 11625 of 12390 in total
4-(2-(1H-IMIDAZOL-4-YL)ETHYLAMINO)-2-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
Experimental
Matched Name: … 4-(2-(1H-IMIDAZOL-4-YL)ETHYLAMINO)-2-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE …
Matched Iupac: … 4-{[2-(1H-imidazol-5-yl)ethyl]amino}-2-(phenylamino)pyrazolo[1,5-a][1,3,5]triazine-8-carbonitrile …
Matched Iupac: … 4-{[2-(1H-imidazol-5-yl)ethyl]amino}-2-(phenylamino)pyrazolo[1,5-a][1,3,5]triazine-8-carbonitrile …
Epratuzumab
Epratuzumab is a humanized monoclonal antibody derived from the murine IG2a monoclonal antibody, LL2 (EPB-2). This agent may subsequently be well matched for use in oncology and the treatment of inflammatory autoimmune disorders, such as lupus.
Investigational
Matched Description: … Epratuzumab is a humanized monoclonal antibody derived from the murine IG2a monoclonal antibody, LL2 ... This agent may subsequently be well matched for use in oncology and the treatment of inflammatory autoimmune …
Cimicoxib
Cimicoxib is a selective COX-2 inhibitor being developed by Affectis as a treatment for depression and schizophrenia. If approved, Cimicoxib would be the first drug in decades to treat depression by a new mechanism of action.
Investigational
Matched Description: … If approved, Cimicoxib would be the first drug in decades to treat depression by a new mechanism of action ... Cimicoxib is a selective COX-2 inhibitor being developed by Affectis as a treatment for depression and …
RI 624
RI 624 is a novel humanized monoclonal antibody that blocks nerve growth factor (NGF), a key mediator of acute and chronic pain. RI 624 is being developed by Rinat and is currently in Phase I clinical trials.
Investigational
Matched Description: … of acute and chronic pain. ... RI 624 is a novel humanized monoclonal antibody that blocks nerve growth factor (NGF), a key mediator …
SNX-5422
SNX-5422 is a synthetic, novel, small molecule Hsp90 Inhibitor. As an oral formulation that demonstrates strong efficacy and tolerability, SNX-5422 is positioned as a breakthrough therapy with broad applicability across a wide range of cancers.
Investigational
Matched Description: … breakthrough therapy with broad applicability across a wide range of cancers. ... SNX-5422 is a synthetic, novel, small molecule Hsp90 Inhibitor. ... As an oral formulation that demonstrates strong efficacy and tolerability, SNX-5422 is positioned as a …
Tricaine
Tricaine (as tricaine methanesulfonate) is white powder used for anesthesia, sedation, or euthanasia of fish. It is also the only anesthetic licensed in the United States for use in fin fish that are intended for human consumption.
Vet approved
Matched Description: … Tricaine (as tricaine methanesulfonate) is white powder used for anesthesia, sedation, or euthanasia of …
Naquotinib
Naquotinib has been used in trials studying the treatment of Solid Tumors, Non-small Cell Lung Cancer, Non-Small-Cell Lung Cancer (NSCLC), Epidermal Growth Factor Receptor Mutations, and Epidermal Growth Factor Receptor (EGFR) Mutations, among others.
Investigational
Matched Description: … Naquotinib has been used in trials studying the treatment of Solid Tumors, Non-small Cell Lung Cancer …
S-3304
S-3304 has been used in trials studying the treatment of Lung Cancer, Solid Tumors, Non Small Cell Lung Cancer, Stage IIIB Non Small Cell Lung Cancer, and Stage IIIA Non Small Cell Lung Cancer, among others.
Investigational
Matched Description: … S-3304 has been used in trials studying the treatment of Lung Cancer, Solid Tumors, Non Small Cell Lung …
Sulfaisodimidine
Sulfaisodimidine also called sulfisomidine is an antibacterial product that has been studied for the treatment of urinary tract infections in the 1950s, however, it is unclear whether this drug has been officially approved for use anywhere .
Experimental
Matched Description: … Sulfaisodimidine also called sulfisomidine is an antibacterial product that has been studied for the treatment of …
EGT-201
EGT-201 is an adeno-associated viral vector serotype 9 (AAV9) vector-based gene therapy consisting of the alpha-N-acetyglucosaminidase (NAGLU) transgene. Developed by Esteve Pharmaceuticals, it is being investigated for Sanfilippo syndrome type B.
Investigational
Matched Description: … EGT-201 is an adeno-associated viral vector serotype 9 (AAV9) vector-based gene therapy consisting of …
RPI-MN
RPI-MN is a detoxified or chemically modified alpha-cobratoxin with antiviral properties. Being developed by Nutra Pharma under the trade name PEPTERON, it is being investigated for the treatment of neurological and immune disorders.
Investigational
Matched Description: … RPI-MN is a detoxified or chemically modified alpha-cobratoxin with antiviral properties. ... developed by Nutra Pharma under the trade name PEPTERON, it is being investigated for the treatment of …
4-Methoxyamphetamine
Experimental
Illicit
Matched Categories: … Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates …
3-Phenylpropylamine
Experimental
Briquilimab
Briquilimab is a humanized aglycosylated IgG1 kappa monoclonal antibody targeting CD117 (cKit).
Investigational
Matched Description: … Briquilimab is a humanized aglycosylated IgG1 kappa monoclonal antibody targeting CD117 (cKit). …
KD3010
KD3010 is a small molecule peroxisome proliferator-activator receptor delta (PPAR Delta) agonist for the treatment of metabolic disorders, including obesity.
Investigational
Matched Description: … the treatment of metabolic disorders, including obesity. ... KD3010 is a small molecule peroxisome proliferator-activator receptor delta (PPAR Delta) agonist for …
TAK-475
TAK-475 is a "squalene synthase inhibitor", a type of cholesterol-lowering drug that has not yet been brought to market.
Investigational
Matched Description: … TAK-475 is a "squalene synthase inhibitor", a type of cholesterol-lowering drug that has not yet been …
CMC 001
CMC 001 is an orally administered MRI contrast agent in development for enhancement of the liver, bile ducts and gastrointestinal tract.
Investigational
Matched Description: … CMC 001 is an orally administered MRI contrast agent in development for enhancement of the liver, bile …
Solabegron
Solabegron (GW-427,353) is a selective β3 adrenoceptor agonist being developed for the treatment of overactive bladder and irritable bowel syndrome.
Investigational
Matched Description: … Solabegron (GW-427,353) is a selective β3 adrenoceptor agonist being developed for the treatment of overactive …
Evacetrapib
Evacetrapib has been used in trials studying the basic science and treatment of Dyslipidemia, Hyperlipidemia, Hypercholesterolemia, Hepatic Insufficiency, and Cardiovascular Disease.
Investigational
Matched Description: … Evacetrapib has been used in trials studying the basic science and treatment of Dyslipidemia, Hyperlipidemia …
Ipatasertib
Ipatasertib has been used in trials studying the treatment of Cancer, Neoplasms, Solid Cancers, Breast Cancer, and Gastric Cancer, among others.
Investigational
Matched Description: … Ipatasertib has been used in trials studying the treatment of Cancer, Neoplasms, Solid Cancers, Breast …
Displaying drugs 11601 - 11625 of 12390 in total